scispace - formally typeset
S

Stanley F. Wolf

Researcher at Genetics Institute, Inc.

Publications -  55
Citations -  11527

Stanley F. Wolf is an academic researcher from Genetics Institute, Inc.. The author has contributed to research in topics: Interleukin 12 & T cell. The author has an hindex of 32, co-authored 55 publications receiving 11356 citations. Previous affiliations of Stanley F. Wolf include Washington University in St. Louis & Pfizer.

Papers
More filters
Journal ArticleDOI

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

TL;DR: This regulatory pathway may have evolved to enable innate immune cells, through interactions with microbial pathogens, to direct development of specific immunity toward the appropriate TH1 phenotype.
Journal Article

Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells.

TL;DR: The synergistic stimulation by NKSF plus IL-2 of T and NK function supports the possibility that these cytokines might prove useful in cancer therapy.
Journal Article

Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

TL;DR: IL-12 is an effective and minimally toxic antitumor agent in murine tumor models and leads to an immune-mediated rejection involving, at least in part, IFN-gamma, CD4+, and CD8+ cells.
Journal ArticleDOI

Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts.

TL;DR: The data argue that IL-12 is required for the T-cell-independent triggering of NK cells by intracellular parasites and that the cytokine may be useful for inducing this protective pathway in immunodeficient hosts.
Journal ArticleDOI

Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist.

TL;DR: Macrophage production of TNF-alpha and IL-12 stimulates the release of IFN-gamma by NK cells and that IL-10 produced in response to hk-LM inhibits this response at the level of the macrophage and the NK cell.